Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).
Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine and infliximab changes serious adverse events compared with infliximab (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with 5‐aminosalicylic acid (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with anti TNF‐α (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in serious adverse events compared with placebo (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with placebo (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).
The findings closest to your search, judged one by one by TypeSafe's Jev model.